# Table of Contents

**July 1, 2014 • Volume 20 • Number 13**

## Highlights of This Issue 3359

### SPECIAL FEATURES

#### CCR Translations

3361  MET as a Target in Papillary Renal Cell Carcinoma  
André P. Fay, Sabina Signoretti, and Toni K. Choueiri  
*See related article, p. 3411*

#### CCR Perspectives in Drug Approval

3364  U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009  
Sonia K. Morgan-Linnell, David J. Stewart, and Razelle Kurzrock

#### Statistics in Clinical Cancer Research

3371  Blocking and Randomization to Improve Molecular Biomarker Discovery  
Li-Xuan Qin, Qin Zhou, Faina Bogomolniy, Liliana Villafania, Narciso Olvera, Magali Cavatore, Jaya M. Satagopan, Colin B. Begg, and Douglas A. Levine

#### Molecular Pathways

3379  Molecular Pathways: CDK4 Inhibitors for Cancer Therapy  
Mark A. Dickson

3384  Molecular Pathways: Niches in Metastatic Dormancy  
Kenji Yamoto, Matthew R. Eber, Janice E. Berry, Russell S. Taichman, and Yusuke Shiozawa

#### Review

3390  Infusions of Allogeneic Natural Killer Cells as Cancer Therapy  
Wing Leung

## HUMAN CANCER BIOLOGY

3401  Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions  
Yong-Chen Lu, Xin Yao, Jessica S. Crystal, Yong F. Li, Mona El-Gamil, Colin Gross, Lindy Davis, Mark E. Dudley, James C. Yang, Yardena Samuels, Steven A. Rosenberg, and Paul F. Robbins

3411  MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array  
Laurence Albiges, Justine Guegan, Audrey Le Formal, Virginie Verkarre, Nathalie Rioux-Leclercq, Mathilde Sibony, Jean-Christophe Bernhard, Philippe Camparo, Zahara Merabet, Vincent Molinie, Yves Allory, Cedric Orear, Sophie Couver, Sophie Gad, Jean-Jacques Patard, and Bernard Escudier  
*See related article, p. 3361*

3422  Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer  
Natalie Hartmann, Nathalia A. Giese, Thomas Gielse, Isabel Poschke, Rienk Offerlinga, Jens Werner, and Eduard Ryschich

3434  Overexpression of Sirt7 Exhibits Oncogenic Property and Serves as a Prognostic Factor in Colorectal Cancer  
Hongyan Yu, Wen Ye, Jiangxue Wu, Xiangqi Meng, Ran-yi Liu, Xiaofang Yang, Yi Zhou, Hui Wang, Changchuan Pan, and Wenlin Huang

## CANCER THERAPY: PRECLINICAL

3446  Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma  
Mohammad Atefi, Earl Avramis, Amanda Lassen, Deborah J.L. Wong, Lidia Robert, David Foulad, Michael Cerniglia, Bjorn Titze, Thibin Chodon, Thomas G. Graeber, Begonya Comin-Anduix, and Antoni Ribas
Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
Ian Judson, Michelle Scurr, Kate Gardner, Elizabeth Barquin, Marcelo Marotti, Barbara Collins, Helen Young, Juliane M. Jürgensmeier, and Michael Leahy

Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations
Mikihiro Kohno, Tatsuro Okamoto, Kenichi Suda, Mototsugu Shimokawa, Hirokazu Kitahara, Shinichiro Shimamatsu, Hideyuki Konishi, Tsukihisa Yoshida, Mitsuhiro Takenoyama, Tokujiro Yano, and Yoshihiko Maehara

SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Letter
Abolfazl Avan, Mina Maftouh, Amir Avan, Carmelo Tibaldi, Paolo A. Zucali, and Elisa Giovannetti

SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Response
Qianxia Li, Huihua Xiong, and Xianglin Yuan

Loss of S6 phosphorylation as a biomarker of response to PI3K/mTOR pathway inhibition. The representative image shows immunohistochemical staining for phosphorylated S6 protein (ser235-236) in SUM190 breast cancer cell line xenografts treated with the pan-PI3K inhibitor BKM120. For details, see the article by O’Brien and colleagues on page 3507 of this issue.